These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34108971)

  • 1. CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1.
    Zeisbrich M; Chevalier N; Sehnert B; Rizzi M; Venhoff N; Thiel J; Voll RE
    Front Immunol; 2021; 12():673912. PubMed ID: 34108971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMTM6, a potential immunotherapy target.
    Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis.
    Singh J; Minz RW; Saikia B; Nada R; Sharma A; Jha S; Anand S; Rathi M; D'Cruz S
    Clin Exp Med; 2023 Sep; 23(5):1801-1813. PubMed ID: 36219364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
    Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
    Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
    Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
    Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis.
    Hakroush S; Tampe B
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
    Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
    Front Immunol; 2019; 10():1638. PubMed ID: 31379838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.
    Miao B; Hu Z; Mezzadra R; Hoeijmakers L; Fauster A; Du S; Yang Z; Sator-Schmitt M; Engel H; Li X; Broderick C; Jin G; Gomez-Eerland R; Rozeman L; Lei X; Matsuo H; Yang C; Hofland I; Peters D; Broeks A; Laport E; Fitz A; Zhao X; Mahmoud MAA; Ma X; Sander S; Liu HK; Cui G; Gan Y; Wu W; Xiao Y; Heck AJR; Guan W; Lowe SW; Horlings HM; Wang C; Brummelkamp TR; Blank CU; Schumacher TNM; Sun C
    Cancer Cell; 2023 Oct; 41(10):1817-1828.e9. PubMed ID: 37683639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis.
    Miyabe C; Dong Y; Ikeda T; Takahashi K; Miyabe Y; Kawakami T
    Sci Rep; 2021 Oct; 11(1):20019. PubMed ID: 34625602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
    Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
    Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
    Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
    Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
    Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
    J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
    J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMTM6 as a master regulator of PD-L1.
    Yaseen MM; Abuharfeil NM; Darmani H
    Cancer Immunol Immunother; 2022 Oct; 71(10):2325-2340. PubMed ID: 35294592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk in ANCA-associated vasculitis: Monocyte phenotyping reveals distinctive signatures between serological subsets.
    Vegting Y; Hanford KM; Jongejan A; Gajadin GR; Versloot M; van der Bom-Baylon ND; Dekker T; Penne EL; van der Heijden JW; Houben E; Bemelman FJ; Neele AE; Moerland PD; Vogt L; Kroon J; Hilhorst ML
    Atherosclerosis; 2024 Oct; 397():118559. PubMed ID: 39186910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CMTM6 and CMTM7: New leads for PD-L1 regulation in breast cancer cells undergoing EMT.
    Xiao M; Duhem C; Chammout A; Berchem G; Janji B
    J Cell Biochem; 2022 Jun; 123(6):1025-1031. PubMed ID: 35575054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma.
    Liu LL; Zhang SW; Chao X; Wang CH; Yang X; Zhang XK; Wen YL; Yun JP; Luo RZ
    Cancer Immunol Immunother; 2021 Feb; 70(2):417-429. PubMed ID: 32770259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4
    de Freitas E Silva R; Gálvez RI; Pereira VRA; de Brito MEF; Choy SL; Lotter H; Bosurgi L; Jacobs T
    Front Immunol; 2020; 11():574491. PubMed ID: 33193363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.